title: [Comparative study of an antiemetic NK1 receptor-antagonist in lung cancer patients treated with divided doses for Cisplatin].
abstract: Aprepitant is a NK1 receptor-antagonist with a novel mechanism of action for chemotherapy-induced nausea and vomiting (CINV), and is recommended as a prophylactic by many international and domestic guidelines. However, domestic clinical trials of aprepitant have only been conducted using a single dose in patients who were treated with cisplatin(CDDP), and there is no evidence to support administration of aprepitant in divided doses. We administered aprepitant in divided doses to patients who were also being treated with cisplatin, ifosfamide, and irinotecan(CIC), and had CINV due to prophylactic administration of a 5-HT3 receptor antagonist and dexamethasone. This was done in order to evaluate the antiemetic effect of aprepitant. The patients with"No vomiting"increased significantly from 25% to 83%, and the"Days with nausea"in patients also decreased significantly. Consequently, administration of aprepitant in addition to current antiemetic therapy in divided doses, as well as in single doses, exhibited a greater antiemetic effect in CDDP-treated patients.
authors.affiliation: Dept. of Pharmacy, Hokkaido Keiaikai Sapporo Minami-Sanjo Hospital, Japan.
authors.forename: Hideki
authors.initials: H
authors.lastname: Sato
authors.forename: Keiko
authors.initials: K
authors.lastname: Wada
authors.forename: Kengo
authors.initials: K
authors.lastname: Umehara
authors.forename: Keisuke
authors.initials: K
authors.lastname: Otsu
authors.forename: Azusa
authors.initials: A
authors.lastname: Wakamoto
authors.forename: Tae
authors.initials: T
authors.lastname: Hatsuyama
authors.forename: Akihisa
authors.initials: A
authors.lastname: Fujita
authors.forename: Kyuichiro
authors.initials: K
authors.lastname: Sekine
mesh_terms: D000932:Antiemetics / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control*; D064729:Neurokinin-1 Receptor Antagonists; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D064729:Neurokinin-1 Receptor Antagonists; D002945:Cisplatin